Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
Cancer Therapies02:49

Cancer Therapies

7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K
Tumor Immunotherapy01:27

Tumor Immunotherapy

529
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
529

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Targeting Phosphatidylserine in Advanced Gastric and Gastroesophageal Junction Adenocarcinomas: A Phase 2 Trial of Bavituximab Plus Pembrolizumab with Biomarker-Correlated Outcomes.

Current oncology (Toronto, Ont.)·2026
Same author

Total Neoadjuvant Approach for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma-UK Tertiary Cancer Centre Experience.

Cancers·2026
Same author

Biomarker-guided immuno-angiogenic therapy in biliary tract cancer: insights from IMbrave151.

Journal of gastrointestinal oncology·2026
Same author

Maintenance capecitabine after first-line platinum-based chemotherapy in advanced oesophagogastric adenocarcinoma: final analysis from the PLATFORM trial.

British journal of cancer·2026
Same author

Correction: Impact of perioperative fluorouracil, leucovorin, oxaliplatin, and docetaxel delivery on postoperative survival in locally advanced oesophagogastric adenocarcinoma.

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association·2025
Same author

New Horizons with Growth Differentiation Factor 15 in Oncology: From Cancer Cachexia and Tumour Immunity to Novel Therapeutic Strategies.

Current oncology (Toronto, Ont.)·2025

Related Experiment Video

Updated: Jul 6, 2025

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

5.2K

Updates on Systemic Therapy for Hepatocellular Carcinoma.

Panagiotis Ntellas1, Ian Chau1

  • 1Department of Medicine, Royal Marsden Hospital, London and Surrey, United Kingdom.

American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting
|January 4, 2024
PubMed
Summary

Recent hepatocellular carcinoma (HCC) treatments show progress. New combinations of immunotherapy and antiangiogenic agents are improving outcomes for advanced HCC, addressing high relapse rates.

More Related Videos

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
00:06

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

8.9K
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

444

Related Experiment Videos

Last Updated: Jul 6, 2025

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

5.2K
An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
00:06

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

8.9K
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

444

Area of Science:

  • Hepatobiliary Cancers
  • Medical Oncology
  • Translational Research

Background:

  • Hepatocellular carcinoma (HCC) presents significant treatment challenges, particularly concerning high recurrence rates after curative therapies.
  • Current treatment paradigms require evolution to address multifocal and advanced-stage disease effectively.

Approach:

  • This review synthesizes recent advancements in HCC treatment strategies across all disease stages.
  • It examines novel therapeutic combinations, including immunotherapy and antiangiogenic agents, and their impact on patient outcomes.

Key Points:

  • Adjuvant and perioperative therapies are under investigation for early-stage HCC to mitigate relapse, with atezolizumab/bevacizumab showing promise.
  • Locoregional treatments are increasingly combined with systemic therapies for multifocal HCC, enhancing efficacy.
  • First-line treatment for advanced HCC has shifted towards combinations like atezolizumab/bevacizumab and tremelimumab/durvalumab, with other agents like tislelizumab and pembrolizumab/lenvatinib emerging.

Conclusions:

  • The landscape of HCC treatment is rapidly evolving, with a focus on novel combination therapies to improve survival and manage advanced disease.
  • Understanding the interplay between immunotherapies and antiangiogenic agents is crucial for optimizing future treatment strategies and decision-making.